Guardant Health, Inc. (GH) News
Filter GH News Items
GH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GH News Highlights
- GH's 30 day story count now stands at 6.
- Over the past 23 days, the trend for GH's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- ALTO, DRUG and PERF are the most mentioned tickers in articles about GH.
Latest GH News From Around the Web
Below are the latest news stories about GUARDANT HEALTH INC that investors may wish to consider to help them evaluate GH as an investment opportunity.
Guardant Health (NASDAQ:GH) shareholders have endured a 78% loss from investing in the stock three years agoGuardant Health, Inc. ( NASDAQ:GH ) shareholders should be happy to see the share price up 13% in the last month. But... |
Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie GiffordPALO ALTO, Calif., December 21, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that it has entered into a common stock purchase agreement with Baillie Gifford on behalf of accounts that it manages for the sale of 3,387,446 shares of its common stock in a registered direct offering at an offering price of $26.77 per share. |
Blood-Based Colorectal Cancer CRC Screening Market Likely to Benefit From FDA's Panel Surprise Advisory Possibility: AnalystTuesday, Guardant Health Inc (NASDAQ: GH) announced that the FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is tentatively scheduled to review the premarket approval application (PMA) for its Shield blood test to screen for colorectal cancer on March 28, 2024. Guardant Health submitted the final module of its PMA for Shield on March 10, 2023. The submission includes data from the ECLIPSE study, an over 20,000-patient registrational study evaluating the perf |
Guardant Health to Participate in the 42nd Annual J.P. Morgan Healthcare ConferencePALO ALTO, Calif., December 20, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco. |
Guardant Health Announces Tentative Date of FDA Advisory Panel Review of Shield™ Blood TestPALO ALTO, Calif., December 19, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is tentatively scheduled to review the premarket approval application (PMA) for the company’s Shield™ blood test to screen for colorectal cancer on March 28, 2024. The date and details of the meeting are subject to confirmation by the FDA and publ |
Insider Sell: CIO Kumud Kalia Divests 5,800 Shares of Guardant Health IncGuardant Health Inc (NASDAQ:GH), a leading precision oncology company, has recently witnessed a significant insider sell by its Chief Information Officer, Kumud Kalia. |
Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development ActivitiesLONDON & PALO ALTO, Calif., December 04, 2023--Cancer Research UK, one of the world’s largest charitable funders of cancer research, its innovation unit, Cancer Research Horizons, and Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a collaboration to explore the sharing of technologies, data, and insights to advance the development and precision of cancer detection and treatment. |
Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detectionPALO ALTO, Calif., November 30, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present data showing the utility of liquid biopsy tests in the management of breast cancer patients at the San Antonio Breast Cancer Symposium, December 5-9 in San Antonio, Texas. Highlights of the eight poster presentations include the use of blood-based testing to identify actionable biomarkers and predict therapy response in advanced breast cancer, and to detect residual diseas |
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PALO ALTO, Calif., November 15, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on November 8, 2023, the Compensation Committee of Guardant’s Board of Directors granted restricted stock units ("RSUs") representing 50,741 shares of its common stock to 43 new non-executive employees under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the "Inducement Plan"). The RSUs were granted as inducements material to the employe |
Guardant Health to Appeal Federal District Court VerdictPALO ALTO, Calif., November 15, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it intends to appeal yesterday’s verdict in the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington. |